Rosuvastatin (Crestor) Safety Profile Differences in Black / African Ancestry Patients

Why Rosuvastatin Safety Differs by Ancestry

Rosuvastatin is the most potent commercially available statin on a milligram-for-milligram basis, producing LDL-C reductions of 45-55% at the 10-20 mg dose range [1]. Its safety profile is generally favorable across populations. But genetic variation in drug transporters, differences in baseline cardiometabolic risk, and gaps in clinical trial representation create a distinct safety field for Black and African ancestry patients that clinicians cannot ignore.

Pharmacokinetic Basics That Matter

Rosuvastatin is not extensively metabolized by cytochrome P450 enzymes. Instead, hepatic uptake depends primarily on OATP1B1 (encoded by SLCO1B1) and biliary efflux depends on BCRP (encoded by ABCG2) [2]. This means genetic variants in these transporters, rather than CYP polymorphisms, drive the meaningful interindividual differences in drug exposure. A patient carrying a loss-of-function ABCG2 variant may have rosuvastatin plasma concentrations up to 144% higher than a wild-type carrier [3].

The Representation Gap

The JUPITER trial (N=17,802), the landmark study that expanded rosuvastatin's indications to primary prevention, enrolled only 6.4% Black participants [4]. That subgroup (approximately 1,277 individuals) showed consistent cardiovascular benefit, with a 37% relative risk reduction in the primary endpoint. The problem is statistical power. Rare safety signals like rhabdomyolysis (incidence <0.1%) require far larger samples to detect population-specific patterns.

Pharmacogenomic Variants Relevant to Black / African Ancestry Patients

Population-level allele frequencies shape which genetic variants matter most in clinical practice. For rosuvastatin, two transporter genes carry the strongest pharmacogenomic evidence, and their variant distributions differ meaningfully across ancestral populations.

ABCG2 (BCRP) 421C>A (rs2231142)

The ABCG2 421C>A variant reduces BCRP transporter function, leading to higher systemic rosuvastatin exposure. According to PharmGKB, the minor allele frequency in populations of African descent is approximately 1-4%, compared with 29-35% in East Asian populations and 9-14% in European populations [3]. This lower prevalence means fewer Black patients carry the high-exposure allele. On an individual basis, a Black patient who does carry 421C>A will experience the same pharmacokinetic consequence: elevated drug levels and a potentially increased risk of dose-dependent adverse effects such as myalgia and hepatotoxicity.

The Clinical Pharmacogenetics Implementation Consortium (CPIC) does not currently issue ancestry-stratified rosuvastatin dosing guidelines specifically for ABCG2, but their 2022 guideline for statins recommends prescribers "consider a lower starting dose or an alternative statin" for patients carrying reduced-function ABCG2 alleles regardless of ancestry [5].

SLCO1B1 521T>C (rs4149056)

This variant in the hepatic uptake transporter OATP1B1 is the best-studied pharmacogenomic predictor of statin-related myopathy. The SEARCH Collaborative Group demonstrated that SLCO1B1 521T>C increased myopathy risk 4.5-fold per copy for simvastatin 80 mg [6]. For rosuvastatin, the effect is smaller but still clinically meaningful: carriers show 60-80% higher plasma AUC values [2].

In African-descent populations, the 521C allele frequency is approximately 2-3%, lower than in Europeans (8-14%) but not negligible [7]. A population pharmacogenomic study published in Clinical Pharmacology & Therapeutics noted that "African Americans exhibit unique SLCO1B1 haplotype structures that may modify rosuvastatin disposition independently of the 521T>C variant alone" [7]. This means standard genotyping panels that test only rs4149056 may miss ancestry-specific haplotype effects.

Myopathy and Rhabdomyolysis Risk

Statin-associated muscle symptoms (SAMS) affect 5-10% of all statin users in observational studies, though randomized controlled trial data suggest a lower true incidence of approximately 1-2% above placebo [8]. The question is whether Black patients face a different myotoxicity risk with rosuvastatin specifically.

What the Data Show

No randomized trial has been powered to compare rosuvastatin myopathy rates by race. FDA Adverse Event Reporting System (FAERS) analyses are limited by underreporting and demographic skew. A 2019 pharmacovigilance review found that Black patients were underrepresented in FAERS statin reports relative to their prescription prevalence, making signal detection unreliable [9].

What we do know: the FDA label for rosuvastatin identifies a dose-exposure relationship for myopathy risk, with the 40 mg dose carrying the highest incidence [1]. Since genetic and clinical factors that raise drug exposure (renal impairment, transporter variants, drug interactions with gemfibrozil or cyclosporine) increase myopathy risk proportionally, Black patients with any of these factors deserve the same cautious monitoring applied to any high-exposure patient.

Practical Monitoring

The American College of Cardiology and American Heart Association (ACC/AHA) 2018 cholesterol guideline recommends checking baseline creatine kinase (CK) only when patients have a prior history of statin intolerance or elevated myopathy risk [10]. For Black patients starting rosuvastatin, a reasonable clinical approach includes: baseline CK, a renal function panel (eGFR using the CKD-EPI 2021 equation, which removed the race coefficient), and a check for concomitant medications that inhibit OATP1B1 or BCRP.

Renal Considerations

Black adults in the United States have an approximately 1.4-fold higher prevalence of chronic kidney disease compared with White adults, driven in part by higher rates of hypertension, diabetes, and APOL1 risk variants [11]. This matters for rosuvastatin because approximately 28% of the drug is eliminated renally [1].

Dose Adjustment in Renal Impairment

The FDA-approved label contraindicates rosuvastatin 40 mg in patients with an eGFR <30 mL/min/1.73 m² and recommends a starting dose of 5 mg for these patients [1]. For patients with moderate renal impairment (eGFR 30-60), no mandatory dose reduction exists, but drug accumulation is measurable. A pharmacokinetic study found that rosuvastatin AUC increased approximately 3-fold in subjects with severe renal impairment compared with healthy volunteers [2].

The eGFR Equation Shift

Until 2021, the widely used MDRD and CKD-EPI equations included a race coefficient that produced higher eGFR estimates for Black patients. The National Kidney Foundation and American Society of Nephrology joint task force recommended removing this coefficient in 2021 [12]. This change means some Black patients who previously appeared to have adequate renal function may now receive lower eGFR values, potentially triggering rosuvastatin dose adjustments that were previously missed. Clinicians prescribing rosuvastatin should confirm their laboratory is using the 2021 CKD-EPI equation.

Cardiovascular Context: Higher Baseline Risk

Black Americans have the highest age-adjusted cardiovascular mortality rate of any racial/ethnic group in the United States [13]. Hypertension prevalence exceeds 55% in Black adults over age 45, compared with approximately 45% in White adults of the same age range [13]. This epidemiologic context shapes the risk-benefit calculation for rosuvastatin in two directions.

The Benefit Side

Higher baseline ASCVD risk means higher absolute benefit from LDL-C lowering. The Cholesterol Treatment Trialists' (CTT) Collaboration meta-analysis of 26 statin trials (N=170,000) found that each 1 mmol/L reduction in LDL-C produced a 22% relative reduction in major vascular events, with absolute benefit scaling linearly with baseline risk [14]. A Black patient with a 10-year ASCVD risk of 15% stands to gain more in absolute terms from rosuvastatin therapy than a lower-risk patient receiving the same relative reduction.

The Safety Side

Higher rates of comorbid CKD, diabetes, and polypharmacy in Black patients increase the probability of drug interactions and dose-dependent toxicity. The 2018 ACC/AHA guideline explicitly calls for a "clinician-patient risk discussion" that accounts for "race/ethnic-specific risk factors" when initiating statin therapy [10]. Dr. Keith Ferdinand, professor of medicine at Tulane University and a leading researcher on cardiovascular disparities, has stated: "We need to stop treating Black patients as if the general population data automatically apply. The comorbidity burden is different, and our monitoring intensity should reflect that" [15].

Drug Interaction Considerations

Rosuvastatin has fewer CYP-mediated drug interactions than simvastatin or atorvastatin. That is a genuine clinical advantage. But transporter-mediated interactions remain relevant.

Key Interactions to Watch

Gemfibrozil increases rosuvastatin AUC by approximately 88% via OATP1B1 inhibition [1]. Cyclosporine raises it 7-fold. Ritonavir-containing HIV regimens increase rosuvastatin exposure 2-fold [1]. Each of these interactions is pharmacokinetically mediated, not CYP-based, meaning they affect all patients carrying functional transporters.

For Black patients specifically, the intersection of HIV treatment and statin therapy is clinically relevant. Black Americans represent approximately 40% of new HIV diagnoses in the United States [16]. Patients on protease inhibitor-based antiretroviral therapy who require statin therapy should use rosuvastatin with caution, starting at 5 mg and titrating slowly with lipid and CK monitoring. The HIV Medicine Association recommends rosuvastatin or pitavastatin as preferred statins in this setting due to fewer overall drug interactions compared with other statins [17].

Antihypertensive Co-prescribing

Calcium channel blockers (CCBs) like amlodipine are first-line antihypertensives in Black patients per JNC 8 and the 2017 ACC/AHA hypertension guideline [18]. Amlodipine does not significantly alter rosuvastatin pharmacokinetics, making this combination safe from an interaction standpoint. ACE inhibitors and ARBs, while showing reduced blood pressure efficacy as monotherapy in Black patients compared with CCBs and thiazides, are still frequently prescribed for renoprotection. These agents do not interact with rosuvastatin either.

Gaps in Evidence and What Comes Next

The single largest problem in characterizing rosuvastatin safety for Black patients is insufficient data. This is not an abstract concern.

Trial Diversity Deficits

A 2020 analysis in JAMA Network Open found that Black participants comprised only 3.2% of enrollees across 36 cardiovascular outcome trials conducted between 2000 and 2019 [19]. The JUPITER trial's 6.4% Black enrollment was above average for its era but still insufficient to detect safety signals with incidence rates below 1%.

Pharmacogenomic Research Gaps

Most genome-wide association studies of statin response have been conducted predominantly in European-ancestry cohorts. The All of Us Research Program, which has enrolled over 413,000 participants with approximately 21% identifying as Black or African American, may eventually provide the pharmacogenomic data needed to refine rosuvastatin safety profiles by ancestry [20]. Until those results mature, clinicians should interpret population-level pharmacogenomic data with the understanding that effect sizes derived from European cohorts may not directly transfer.

The 2022 CPIC statin guideline acknowledges this gap directly: "The majority of evidence for SLCO1B1-guided statin prescribing comes from studies in European-descent populations, and the applicability to other populations requires further study" [5].

Clinical Recommendations for Prescribers

Start rosuvastatin at the standard recommended dose for the patient's ASCVD risk category. Do not empirically reduce the dose based on race alone. Confirm eGFR using the 2021 CKD-EPI equation without a race coefficient. Check for concomitant medications that inhibit OATP1B1 or BCRP, with particular attention to protease inhibitors and gemfibrozil. Consider pharmacogenomic testing for SLCO1B1 and ABCG2 if available, especially in patients with prior statin intolerance. Monitor CK and hepatic function at baseline and 4-12 weeks after initiation. Schedule lipid panels at 4-12 weeks to confirm LDL-C response, and reassess annually. If muscle symptoms develop, measure CK and consider dose reduction or a switch to a lower-intensity statin before discontinuing therapy entirely. The ACC/AHA 2018 guideline's recommendation to engage in shared decision-making applies with particular force here, where comorbidity burden and polypharmacy prevalence are higher than in the general population [10].